Zoetis Inc. (ZTS)
NYSE: ZTS · Real-Time Price · USD
145.36
-1.06 (-0.72%)
Oct 6, 2025, 4:00 PM EDT - Market closed
Zoetis Revenue
Zoetis had revenue of $2.46B in the quarter ending June 30, 2025, with 4.19% growth. This brings the company's revenue in the last twelve months to $9.39B, up 5.27% year-over-year. In the year 2024, Zoetis had annual revenue of $9.26B with 8.33% growth.
Revenue (ttm)
$9.39B
Revenue Growth
+5.27%
P/S Ratio
6.95
Revenue / Employee
$680,072
Employees
13,800
Market Cap
64.42B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.26B | 712.00M | 8.33% |
Dec 31, 2023 | 8.54B | 464.00M | 5.74% |
Dec 31, 2022 | 8.08B | 304.00M | 3.91% |
Dec 31, 2021 | 7.78B | 1.10B | 16.49% |
Dec 31, 2020 | 6.68B | 415.00M | 6.63% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ZTS News
- 3 days ago - Top 50 High-Quality Dividend Growth Stocks For October 2025 - Seeking Alpha
- 5 days ago - Top 15 High-Growth Dividend Stocks For October 2025 - Seeking Alpha
- 6 days ago - Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle - Business Wire
- 10 days ago - Pet Pain For Investor Gain - Seeking Alpha
- 13 days ago - Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results - Business Wire
- 24 days ago - Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats - Business Wire
- 4 weeks ago - Zoetis Inc. (ZTS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Top 50 High-Quality Dividend Stocks For September 2025 - Seeking Alpha